

Resource Summary Report

Generated by [RRID](#) on Jul 31, 2026

Vimentin antibody [EPR3776]

RRID:AB_10562134

Type: Antibody

Proper Citation

Abcam Cat# ab92547, RRID:AB_10562134

Antibody Information

URL: http://antibodyregistry.org/AB_10562134

Proper Citation: Abcam Cat# ab92547, RRID:AB_10562134

Target Antigen: Vimentin antibody [EPR3776]

Host Organism: rabbit

Clonality: monoclonal

Comments: validation status unknown, seller recommendations provided in 2012: Flow Cyt, ICC, ICC/IF, IHC-P, IP, WB; Immunocytochemistry; Immunoprecipitation; Immunohistochemistry - fixed; Western Blot; Flow Cytometry; Immunofluorescence; Immunohistochemistry

Info: Independent validation by the NYU Lagone was performed for: IHC. This antibody was found to have the following characteristics: Functional in human:FALSE, NonFunctional in human:FALSE, Functional in animal:TRUE, NonFunctional in animal:FALSE

Antibody Name: Vimentin antibody [EPR3776]

Description: This monoclonal targets Vimentin antibody [EPR3776]

Target Organism: rat, mouse, human

Antibody ID: AB_10562134

Vendor: Abcam

Catalog Number: ab92547

Record Creation Time: 20250820T011909+0000

Record Last Update: 20250820T103637+0000

Ratings and Alerts

- Independent validation by the NYU Lagone was performed for: IHC. This antibody was found to have the following characteristics: Functional in human:FALSE, NonFunctional in human:FALSE, Functional in animal:TRUE, NonFunctional in animal:FALSE - NYU Langone's Center for Biospecimen Research and Development <https://med.nyu.edu/research/scientific-cores-shared-resources/center-biospecimen-research-development>

No alerts have been found for Vimentin antibody [EPR3776].

Data and Source Information

Source: [Antibody Registry](#)

Usage and Citation Metrics

We found 143 mentions in open access literature.

Listed below are recent publications. The full list is available at [RRID](#) .

Galeano Niño JL, et al. (2026) Tumor-infiltrating bacteria disrupt cancer epithelial cell interactions and induce cell-cycle arrest. *Cancer cell*, 44(1), 166.

Weigl EJ, et al. (2026) An intestinal matrix-based human lung cancer model reflects clinical data from gefitinib on dosage-dependent efficacy. *Toxicology and applied pharmacology*, 506, 117625.

Sakai T, et al. (2025) Establishment of a 3D spheroid culture system to evaluate the responsiveness of uterine leiomyoma cells to female hormones. *Reproductive medicine and biology*, 24(1), e12627.

Li Y, et al. (2025) Single-Cell Transcriptomic Landscape Deciphers Intratumoral Heterogeneity and Subtypes of Acral and Mucosal Melanomas. *Clinical cancer research : an official journal of the American Association for Cancer Research*, 31(12), 2495.

Yong Y, et al. (2025) AMIGO2 characterizes cancer-associated fibroblasts in metastatic colon cancer and induces the release of paracrine active tumorigenic secretomes. *The Journal of pathology*, 265(1), 14.

Yamashita K, et al. (2025) Ezrin, radixin, and moesin are novel citrullinated proteins in the decidua during pregnancy†. *Biology of reproduction*.

Thapa R, et al. (2025) Single-nucleus RNA sequencing reveals GABAergic vulnerability and reactive gliosis driven by loss of TDP-43. *iScience*, 28(11), 113745.

Nakamura Y, et al. (2025) Adult leptomeningeal vestigial neural crest-derived multipotent cells promote vascular repair after stroke. *Cell reports*, 45(1), 116747.

Engel K, et al. (2025) Segment specific loss of NFAT5 function in the kidneys is sufficient to induce a global kidney injury like phenotype. *FASEB journal : official publication of the Federation of American Societies for Experimental Biology*, 39(2), e70352.

Saha S, et al. (2025) Fibrillarin regulates epithelial integrity via EZH2-mediated modulation of scribble expression. *Cell reports*, 44(12), 116608.

Wang B, et al. (2025) Targeting CTGF overcomes resistance to CSF1R inhibitors by preventing CAF activation in colorectal cancer. *Cell reports. Medicine*, 6(12), 102480.

Huang S, et al. (2025) Low-intensity-pulsed-ultrasound-treated menstrual-blood-derived mesenchymal stem cells repair endometrial injury by PI3K/AKT pathway inhibition. *Reproductive biomedicine online*, 50(3), 104486.

Sato S, et al. (2025) Effects of female hormone withdrawal and ulipristal acetate on MED12 mutation positive and negative uterine leiomyomas using a xenograft model. *Scientific reports*, 15(1), 40028.

Nam JK, et al. (2025) Combined HIF-1 α blockade and CHIR99021 treatment reverses pulmonary fibrosis via modulation endothelial-to-mesenchymal transition. *iScience*, 28(12), 114028.

Li F, et al. (2025) Phosphoproteomics profiling of sorafenib-resistant hepatocellular carcinoma patient-derived xenografts reveals potential therapeutic strategies. *iScience*, 28(1), 111657.

Chen L, et al. (2025) Sophoridine inhibits proliferation and migration by targeting PIM1 in breast cancer. *Pharmaceutical biology*, 63(1), 503.

Tomé D, et al. (2025) Mesenchymal stromal cell secretome-induced synaptogenesis is mediated by thrombospondin-1. *iScience*, 28(9), 113401.

Zhao S, et al. (2025) Targeting ECM-producing cells with CAR-T therapy alleviates fibrosis in chronic kidney disease. *Cell stem cell*, 32(9), 1390.

Wang X, et al. (2025) Alternative splicing of EZH2 regulated by SNRNPB mediates hepatocellular carcinoma progression via BMP2 signaling pathway. *iScience*, 28(1), 111626.

Wang K, et al. (2025) Fibrogenesis-driven tumor progression in clear cell renal cell carcinoma: prognostic, therapeutic implications and the dual role of neuropilin-1. *Cancer cell international*, 25(1), 179.